CNS Pharmaceuticals, Inc. Annual report pursuant to Section 13 and 15(d)

Annual report pursuant to Section 13 and 15(d)

4. Equity (Details Narrative)

4. Equity (Details Narrative) - USD ($)	1 Months Ended	4 Months Ended	5 Months Ended	10 Months Ended	11 Months Ended	12 Months Ended
4. Equity (Details Narrative) - USD ($)	Dec. 28, 2020	Apr. 17, 2019	Jun. 03, 2019	Nov. 13, 2019	Nov. 20, 2019	Dec. 31, 2020	Dec. 22, 2020	Dec. 31, 2019	Dec. 31, 2018	Dec. 31, 2017
Stock issued for services, value								$ 150,000
Share-based compensation expense						$ 1,293,392		477,096
Value of stock issued						14,115,485
Deferred offering cost						334,138		$ 0
Term								10 years
Fair value of warrant issued						14,222,249		$ 10,294,747
Fair value of warrants outstanding						$ 0		150,000
Minimum [Member]
Term						5 years 6 months
Maximum [Member]
Term						6 years 3 months 19 days
2017 Stock Plan [Member]
Shares authorized under plan										2,000,000
Options remaining to be issued						0
2020 Stock Plan [Member]
Shares authorized under plan						3,000,000
Options remaining to be issued						2,799,264
Warrants [Member]
Proceeds from issuance of stock	$ 10,590,000
Warrant exercise price	$ 2.20
Fair value of common stock	$ 1.85
Term	5 years
Volatility	130.30%
Risk free interest rate	0.38%
Warrant issued	2,875,000
Fair value of warrant issued	$ 4,485,441
Options [Member]
Share-based compensation expense								$ 400,834
Options granted						561,236		1,189,500
Option exercise price						$ 2.27		$ 2.5
Unrecognized compensation expense						$ 2,258,502		$ 2,753,499
Aggregate intrinsic value options outstanding						528,599
Options [Member] \| Minimum [Member]
Share-based compensation expense						$ 1,208,154
Option exercise price						$ 2.06		$ 2.00
Options [Member] \| Maximum [Member]
Option exercise price						$ 2.47		$ 4.00
Warrants [Member]
Share-based compensation expense						$ 85,238		$ 76,262
Warrant exercise price						$ 3.24		$ 3.99	$ 4.08
Unrecognized compensation expense						$ 0
Warrants granted						2,875,000		312,500
Warrant term						3 years 7 months 13 days
Aggregate intrinsic value of warrants						$ 2,657,317
SAFE Agreements [Member]
Proceeds from SAFE agreements									$ 628,558
SAFE agreement liability									$ 763,249
Stock issued new, shares				191,151
SAFE funds allocated to issue stock				$ 269,399
I P O [Member]
Stock issued new, shares				2,125,000	318,750
Proceeds from IPO				$ 7,601,827	$ 1,185,750
Underwriting fees and other offering expenses				$ 898,173	$ 89,250
Bridge Offering [Member]
Proceeds from issuance of stock								$ 1,507,170
Stock issued new, shares								817,500
Public offering [Member] \| Underwriting Agreement [Member]
Warrant purchased							2,500,000
Warrant expiry date							Dec. 28, 2025
Warrant exercise price							$ 2.20
Consultant [Member]
Stock issued for compensation, shares								75,000
Share-based compensation expense								$ 150,000
Lincoln Park [Member] \| Purchase Agreement [Member]
Proceeds from issuance of stock						$ 3,632,249
Common stock issued for commitment fee						201,991
Value of stock issued						$ 395,902
Legal fees						45,000
Deferred offering cost						106,764
Unamortized deferred offering						$ 334,138
Common stock sold , shares						1,453,926
Foreign Broker [Member] \| Warrants [Member]
Warrants granted		63,750
Fair value of warrants outstanding		$ 101,206
Benchmark [Member] \| Warrants [Member]
Warrant exercise price			$ 4.00
Warrants granted			148,750			148,750
Warrant term			5 years
Fair value of warrants outstanding						$ 451,722